Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease

Alfonso Gomez-Iturriaga; Daniel Spratt; Felipe Counago; Ivan Henriquez; Oscar Abuchaibe

文献导航

搜索文章

搜索思路

钛学术文献服务平台 \
学术期刊 \
医药卫生科技期刊 \
临床医学期刊 \
世界临床肿瘤学杂志：英文版期刊 \
Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease

Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease

作者：

Alfonso Gomez-Iturriaga Daniel Spratt Felipe Counago Ivan Henriquez Oscar Abuchaibe

基本信息来源于合作网站，原文需代理用户跳转至来源网站获取

Nonmetastatic

castration-resistant

prostate

cancer

Prostate

cancer

Apalutamide

Enzalutamide

Darolutamide

TOXICITY

摘要：

Nonmetastatic castration-resistant prostate cancer(nmCRPC)-defined as prostate-specific antigen(PSA)>2 ng/mL,testosterone castration levels<1.7 nm/L,and the absence of metastatic lesions on conventional imaging(computed tomography or bone scan)-has been defined as a lethal disease by the Prostate Cancer Work Group.One-third of patients with prostate cancer who receive androgen deprivation therapy for biochemical recurrence after local treatment will develop CRPC,with death occurring an average of 2.5 years after diagnosis of castration resistance.Most patients diagnosed with nmCRPC are asymptomatic or minimally symptomatic at diagnosis due to local treatment.In patients with short PSA doubling times(<10 mo)and high baseline PSA levels,there is a high risk of bone metastases followed by prostate cancer-related mortality.These patients also present significant morbidity that negatively impacts quality of life(QoL).Recently,the results of three randomized trials(PROSPER,SPARTAN,and ARAMIS)were published.Those trials evaluated the efficacy of three different androgen receptor inhibitors-enzalutamide,apalutamide,and darolutamide-in patients with nmCRPC.In all three trials,the study drugs improved both metastasis-free survival and overall survival compared to placebo,plus on-going androgen deprivation therapy without a negative impact on QoL.In patients with nmCRPC,the most important clinical objective is early detection and treatment to maintain a low tumor burden and to prolong the symptom-free interval.For patients with nmCRPC,these novel drugs offer new hope for better QoL and survival outcomes.

内容分析

关键词云

关键词热度

相关文献

推荐文献

根据相关规定，获取原文需跳转至原文服务方进行注册认证身份信息

完成下面三个步骤操作后即可获取文献，阅读后请点击下方页面【继续获取】按钮

钛学术文献服务平台

学术出版新技术应用与公共服务实验室出品

原文合作方

获取文献流程

1.访问原文合作方请等待几秒系统会自动跳转至登录页，首次访问请先注册账号，填写基本信息后，点击【注册】

2.注册后进行实名认证，实名认证成功后点击【返回】

3.检查邮箱地址是否正确，若错误或未填写请填写正确邮箱地址，点击【确认支付】完成获取，文献将在1小时内发送至您的邮箱

*若已注册过原文合作方账号的用户，可跳过上述操作，直接登录后获取原文即可

点击【获取原文】按钮，跳转至合作网站。

首次获取需要在合作网站进行注册。

注册并实名认证，认证后点击【返回】按钮。

确认邮箱信息，点击【确认支付】，订单将在一小时内发送至您的邮箱。

* 若已经注册过合作网站账号，请忽略第二、三步，直接登录即可。

期刊分类
期刊（年）
期刊（期）
期刊推荐

中医学中药学临床医学儿科学内分泌腺及全身性疾病医学教育与医学边缘学科医药卫生方针政策与法律法规研究医药卫生综合口腔科学妇产科学心血管系统疾病感染性疾病及传染病消化系统疾病皮肤病与性病眼科与耳鼻咽喉科神经病学肿瘤学药学预防医学与卫生学

世界临床肿瘤学杂志：英文版2021 世界临床肿瘤学杂志：英文版2020

世界临床肿瘤学杂志：英文版2021年第2期世界临床肿瘤学杂志：英文版2021年第1期

按字母查找期刊：

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
其他

联系合作广告推广: shenyukuan@paperpass.com

篇名	Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease
来源期刊	世界临床肿瘤学杂志:英文版	学科	医学
关键词	Nonmetastatic castration-resistant prostate cancer Prostate cancer Apalutamide Enzalutamide Darolutamide TOXICITY
年，卷（期）	2021,（1）	所属期刊栏目
研究方向		页码范围	6-12
页数	7页	分类号	R73
字数		语种
DOI